Cargando…
Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials
Ocular toxicities arising from anti-cancer drugs occur sporadically and are sometimes underestimated because they are not life-threatening. Reports focusing on ocular toxicities from cancer therapy are limited. We investigated the detailed progress of ocular toxicities of anti-cancer drugs including...
Autores principales: | Takamizawa, Shigemasa, Katsuya, Yuki, Chen, Yi-Ning, Mizuno, Takaaki, Koyama, Takafumi, Sudo, Kazuki, Yoshida, Tatsuya, Kondo, Shunsuke, Iwasa, Satoru, Yonemori, Kan, Shimizu, Toshio, Yamamoto, Noboru, Suzuki, Shigenobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030433/ https://www.ncbi.nlm.nih.gov/pubmed/36471215 http://dx.doi.org/10.1007/s10637-022-01321-8 |
Ejemplares similares
-
Practical consideration for successful sequential tumor biopsies in first-in-human trials
por: Koyama, Takafumi, et al.
Publicado: (2022) -
Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital
por: Uehara, Yuji, et al.
Publicado: (2023) -
First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2)
receptor 4, alone and with nivolumab in solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2022) -
A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2021) -
First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
por: Koyama, Takafumi, et al.
Publicado: (2020)